1. Home
  2. CBNK vs AURA Comparison

CBNK vs AURA Comparison

Compare CBNK & AURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

CBNK

Capital Bancorp Inc.

HOLD

Current Price

$29.38

Market Cap

440.4M

Sector

Finance

ML Signal

HOLD

Logo Aura Biosciences Inc.

AURA

Aura Biosciences Inc.

HOLD

Current Price

$6.57

Market Cap

377.2M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CBNK
AURA
Founded
1974
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Major Banks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
440.4M
377.2M
IPO Year
2018
2021

Fundamental Metrics

Financial Performance
Metric
CBNK
AURA
Price
$29.38
$6.57
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$34.50
$20.20
AVG Volume (30 Days)
34.7K
229.4K
Earning Date
04-27-2026
03-20-2026
Dividend Yield
1.67%
N/A
EPS Growth
60.85
9.33
EPS
3.41
N/A
Revenue
N/A
N/A
Revenue This Year
$16.20
N/A
Revenue Next Year
$8.52
N/A
P/E Ratio
$8.43
N/A
Revenue Growth
N/A
N/A
52 Week Low
$24.69
$4.73
52 Week High
$36.40
$7.48

Technical Indicators

Market Signals
Indicator
CBNK
AURA
Relative Strength Index (RSI) 53.58 63.58
Support Level $27.55 $5.83
Resistance Level $33.33 $6.67
Average True Range (ATR) 0.93 0.40
MACD 0.04 0.07
Stochastic Oscillator 68.35 75.72

Price Performance

Historical Comparison
CBNK
AURA

About CBNK Capital Bancorp Inc.

Capital Bancorp Inc is a bank holding company. The company through its holdings operates as a commercial-focused community bank that serves businesses, not-for-profit associations, and entrepreneurs throughout the region. The bank operates through four divisions including Commercial Banking, Capital Bank Home Loans, OpenSky, and Windsor Advantage, and also operates in five business segments: commercial banking; mortgage banking; credit cards; government loan servicing; and corporate activities.

About AURA Aura Biosciences Inc.

Aura Biosciences Inc is a clinical-stage biotechnology company developing precision immunotherapies to treat a range of solid tumors designed to preserve the function of organs afflicted with cancer. Its candidate bel-sar is in late-stage clinical development for the treatment of patients with primary choroidal melanoma, and other ocular oncology indications as well as in early-stage clinical development in bladder cancer. The Company views its operations and manages its business in one operating segment operating exclusively in the United States.

Share on Social Networks: